



# Divide and conquer: towards isoform-specific diagnosis and therapy of *KRAS*-mutant lung cancer

Anna T. Allemann, Oliver Gautschi

Medical Oncology and Cancer Center, Cantonal Hospital of Lucerne, Lucerne, Switzerland

Correspondence to: Anna T. Allemann, MD. Medical Oncology and Cancer Center, Cantonal Hospital of Lucerne, Spitalstrasse, 6000 Lucerne, Switzerland. Email: annateresa.allemann@luks.ch.

Comment on: Ricciuti B, Son J, Okoro JJ, et al. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of *KRAS* Mutations in Non-Small Cell Lung Cancer. *Clin Cancer Res* 2022;28:1640-50.

**Keywords:** *KRAS*; lung cancer; isoform specificity; targeted therapy; precision medicine

Submitted Feb 01, 2023. Accepted for publication May 08, 2023. Published online May 24, 2023.

doi: 10.21037/tlcr-23-72

View this article at: <https://dx.doi.org/10.21037/tlcr-23-72>

The identification of oncogenes in animal cells by experiments with retroviruses, and the discovery that similar genetic alterations can cause tumours in humans, laid the foundation for modern cancer research. From that pioneering work to the current genomic era, *RAS* genes marked the beginning of molecular oncology, and remained at the forefront of cancer research ever since.

In humans, the three genes *HRAS*, *NRAS* and *KRAS* encode four proteins: H-Ras (Harvey-Ras), N-Ras (Neuroblastoma-Ras) and two isoforms of K-Ras (Kirsten-Ras), K-Ras4A and K-Ras4B, which in turn derive from alternative splicing isoforms (1). These oncoproteins are members of a larger superfamily of small guanine triphosphatase (GTPase), containing over 170 proteins, which are divided into five main branches on the basis of protein structure, function or both: Ras, Rho, Rab, Ran and Arf (2,3). All Ras isoforms are characterised by two main domains: a highly conserved catalytic domain, and a farnesylated hypervariable region that modulates membrane interaction for distinctive localizations. The catalytic domain contains the guanine triphosphate (GTP)-guanine diphosphate (GDP) binding site and interaction sites with effector proteins: because it is identical in all Ras isoforms, all the proteins can interact with the same set of downstream effectors (4). Similar to all the *RAS* proteins, Kras functions as binary molecular switch in the regulation of pathways responsible for cell proliferation and survival. When stimulated by mitogenic signals, Kras binds to GTP,

and activates downstream molecules and effectors. When the stimulation is terminated, Kras-GTP switches to Kras-GDP. Given the slow intrinsic hydrolysis rate of Kras, deactivation of the signal depends critically on GTPase activating protein (GAP), that enhances the GTPase activity and leads Kras to an inactive state (1,4).

Due to differences in post-translational modifications of Ras, including farnesylation, geranylgeranylation and palmitoylation, and because of different intracellular localizations at the plasma membrane and the endomembranes, Ras proteins have access to different effector pools, and are thus able to generate distinct signals (1,5). More than 20 downstream effector signalling pathways responsible for basic cellular process have been identified, including the serine/threonine protein kinase Raf, MAPK and ERK kinase (MEK), extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway, and the phosphatidylinositol-3-kinase (PI3K)-protein kinase B (PKB/AKT) pathway.

Mutations in *RAS* proto-oncogenes are present in about 20% of all human cancers. *KRAS* mutations are responsible for 75% of adenocarcinomas, while *NRAS* and *HRAS* are mutated more often in melanomas and squamous epithelial carcinomas, respectively. The highest prevalence of *KRAS* mutations are found in pancreatic adenocarcinomas (90%), appendiceal adenocarcinomas (60%), small bowel adenocarcinomas (50%), and colorectal carcinomas (50%) (6,7). *KRAS* mutated lung adenocarcinomas represent about

25% to 30% of all lung cancers, but cannot be considered as a homogeneous entity anymore. Indeed, different isoforms are known: 80% of *KRAS* mutations occur at codon 12 and 13 of exon 2, with G12C the most common form (40%), followed by G12V (about 20%) and G12D (about 15%). Very few mutations are observed at codon 61 of exon 3, which instead is common in *NRAS* mutated cancer. Mutational heterogeneity can be in part explained by tissue exposure to mutagenic agents and specific molecular regulatory mechanisms. For example, exposure to tobacco smoke shows a distinctive coupling to *KRAS*-driven non-small cell lung cancer (NSCLC), especially to G12C variants. This specific mutation is common in former and current smokers, and rarely exists in never-smokers (4,8,9). *KRAS*-mutated lung cancers are characterised by high tumor mutation burden (TMB), a genetic signature of direct tobacco smoke exposure with predominant C>A (G>T) transversion mutations and elevated markers of immune evasion (high PD-L1 expression) (8,10,11). Patients are predominantly female (58%), median age is 65 years, and with history of smoking (93%) (8,12). *KRAS* mutations have been linked to a poor prognosis compared to epidermal growth factor receptor (*EGFR*)-mutated and *KRAS*-wild type lung cancer. Isoform specific outcomes are not consistent across studies. Patients with *KRAS* codon 13 mutations appear to have shorter overall survival compared with patients with codon 12 mutations, G12C and G12V are associated with worse progression-free survival compared with other G12X mutations or wild-type *KRAS* (13-16).

Although no significant differences in survival and demographic data were observed according to the different *KRAS* G12X variants, distinct genomic and transcriptomic features, location and variant type are important factors for oncogenic potential, activation of distinct signalling pathways, and allele-specific genomic landscapes (10,12).

In their article “*Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer*”, Ricciuti *et al.* show that *KRAS* mutational isoforms correlate with distinct biological and genomic profiles, clinical phenotypes and therapeutic outcomes (17). Based on *in vitro* and *in vivo* analysis the authors demonstrate that *KRAS* G12D has the highest oncogenic potential of all the variants analysed. Although no difference in PD-L1 expression was observed between the isoforms, *KRAS* G12D was associated with the lowest tumour mutational burden. These results are important and consistent with previous data published recently (10).

*KRAS* mutations may confer insensitivity to inhibitors of upstream and downstream signalling pathways. Ricciuti *et al.* observe that the MEK-inhibitor trametinib presents similar anti-proliferative effects in all *KRAS*-isoforms, whereas sensitivity to selumetinib, another MEK-inhibitor, is different across the isoforms, with 12C and Q61H being the most responsive. Selumetinib *in vivo* exerts a better response in G12C than sotorasib. The authors postulate delayed feedback mechanisms for MEK inhibitors compared with *KRAS* G12C inhibitors as a single agent. Interestingly, the combined treatment with selumetinib and sotorasib is more effective than either drug alone, leading to significant size reduction of *KRAS* mutated tumours in mice. Also, the combined SH2 containing protein tyrosine phosphatase-2 (SHP2)/MEK inhibition is efficacious, principally in G12C, G12D and G12V mutants compared with other *KRAS* mutants. This observation is consistent with previous experiments and is relevant because SHP2 play an important role in several types of cancer (18). Numerous combination trials with *KRAS* and other MAPK pathway (SHP2/MEK/ERK) inhibitors are in progress (NCT04185883, NCT05480865).

In the analysis of the co-mutational landscape and gene-expression profiles, Ricciuti *et al.* demonstrate that each genomic variant presents specific patterns: mutations in serine/threonine kinase 11 (*STK11*) and ataxia telangiectasia mutated (*ATM*) genes were significantly enriched in tumours harbouring G12C, G12A, or G12V, while G13X mutations were associated with the highest rate of concomitant *STK11* and Kelch-like ECH-associated protein 1 (*KEAP1*)-mutations. *STK11/KEAP1* co-mutations downregulate pathways of innate and adaptive immunity, which in turn are associated with reduced response to PD(L)-blockade (19,20). These results are in accordance with previous observations, suggesting a link between *KRAS*, the genomic landscape, and the immune system (20,21).

The recent approval by Food and Drug Administration (FDA) of sotorasib and adagrasib, two selective and irreversible inhibitors of *KRAS* G12C, is an important milestone in the treatment of patients with metastatic lung cancer (22,23). Further advances in the field of *KRAS* mutant cancers can be expected from combination therapies, as evidenced by recently published results about the combination of adagrasib and cetuximab in colorectal carcinoma (24). In consonance with the results by Ricciuti *et al.*, broader genomic and transcriptomic characterisation of *KRAS* mutant tumours is an important basis for the

research of further combination therapies. This, and the development of compounds targeting *KRAS* mutations other than G12C, necessitates an accurate molecular sub-classification and a broader view on the genomic landscape in *KRAS* mutated cancers.

## Acknowledgments

*Funding:* None.

## Footnote

*Provenance and Peer Review:* This article was commissioned by the editorial office, *Translational Lung Cancer Research*. The article did not undergo external peer review.

*Conflicts of Interest:* Both authors have completed the ICMJE uniform disclosure form (available at <https://tldr.amegroups.com/article/view/10.21037/tlcr-23-72/coif>). ATA participated in an Advisory Board by Janssen, presented a lecture for Janssen and for Astra Zeneca. All honoraria were paid to institution. ATA received support for attending meeting by Janssen. OG was a consultant for AMGEN, participated in advisory boards by Amgen, Roche and Pfizer, and is a member of data safety monitoring board for Boehringer Ingelheim. All honoraria were paid to institution. The authors have no other conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

- Li S, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot. *Nat Rev Cancer* 2018;18:767-77.
- Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. *J Cell Sci* 2005;118:843-6.
- Colicelli J. Human RAS superfamily proteins and related GTPases. *Sci STKE* 2004;2004:RE13.
- Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. *Cancer Res* 2012;72:2457-67.
- Hancock JF. Ras proteins: different signals from different locations. *Nat Rev Mol Cell Biol* 2003;4:373-84.
- Prior IA, Hood FE, Hartley JL. The Frequency of Ras Mutations in Cancer. *Cancer Res* 2020;80:2969-74.
- Lee JK, Sivakumar S, Schrock AB, et al. Comprehensive pan-cancer genomic landscape of *KRAS* altered cancers and real-world outcomes in solid tumors. *NPJ Precis Oncol* 2022;6:91.
- Salem ME, El-Refai SM, Sha W, et al. Landscape of *KRAS*(G12C), Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in *KRAS*-Mutated Cancers. *JCO Precis Oncol* 2022;6:e2100245.
- Le Calvez F, Mukeria A, Hunt JD, et al. TP53 and *KRAS* mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. *Cancer Res* 2005;65:5076-83.
- Judd J, Abdel Karim N, Khan H, et al. Characterization of *KRAS* Mutation Subtypes in Non-small Cell Lung Cancer. *Mol Cancer Ther* 2021;20:2577-84.
- Alexandrov LB, Ju YS, Haase K, et al. Mutational signatures associated with tobacco smoking in human cancer. *Science* 2016;354:618-22.
- El Osta B, Behera M, Kim S, et al. Characteristics and Outcomes of Patients With Metastatic *KRAS*-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. *J Thorac Oncol* 2019;14:876-89.
- Ihle NT, Byers LA, Kim ES, et al. Effect of *KRAS* oncogene substitutions on protein behavior: implications for signaling and clinical outcome. *J Natl Cancer Inst* 2012;104:228-39.
- Yu HA, Sima CS, Shen R, et al. Prognostic impact of *KRAS* mutation subtypes in 677 patients with metastatic lung adenocarcinomas. *J Thorac Oncol* 2015;10:431-7.
- Johnson ML, Sima CS, Chافت J, et al. Association of *KRAS* and *EGFR* mutations with survival in patients with advanced lung adenocarcinomas. *Cancer* 2013;119:356-62.
- Muthiah A, Chudasama R, Mingrino J, et al. Clinical characteristic and outcomes of *KRAS* G13 mutant non-small cell lung cancers. *J Clin Oncol* 2022;40:abstr e21017.
- Ricciuti B, Son J, Okoro JJ, et al. Comparative Analysis

- and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. *Clin Cancer Res* 2022;28:1640-50.
18. Ruess DA, Heynen GJ, Ciecieski KJ, et al. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. *Nat Med* 2018;24:954-60.
  19. Ricciuti B, Arbour KC, Lin JJ, et al. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. *J Thorac Oncol* 2022;17:399-410.
  20. Skoulidis F, Byers LA, Diao L, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. *Cancer Discov* 2015;5:860-77.
  21. Scharpf RB, Balan A, Ricciuti B, et al. Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers. *Cancer Res* 2022;82:4058-78.
  22. Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation. *N Engl J Med* 2022;387:120-31.
  23. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. *N Engl J Med* 2021;384:2371-81.
  24. Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. *N Engl J Med* 2023;388:44-54.

**Cite this article as:** Allemann AT, Gautschi O. Divide and conquer: towards isoform-specific diagnosis and therapy of KRAS-mutant lung cancer. *Transl Lung Cancer Res* 2023;12(6):1328-1331. doi: 10.21037/tlcr-23-72